小林和史

研究者氏名	小林和史
	コバヤシカズフミ
URL
所属	千葉大学
部署	大学院医学研究院　消化器内科学
職名
学位	医学博士(千葉大学)
科研費研究者番号	40836615
J-Global ID	202101015962864350

論文

<123 4 5 >

Shear waveエラストグラフィの汎用性向上を目指した測定方法確立への試み

藤本健太郎近藤孝行藤原希彩子小林和史中村昌人清野宗一郎叶川直哉小笠原定久中本晋吾加藤直也

超音波医学 50(Suppl.) S571-S571 2023年4月

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.

Sae Yumita Sadahisa Ogasawara Miyuki Nakagawa Susumu Maruta Tomomi Okubo Norio Itokawa Yotaro Iino Masamichi Obu Yuki Haga Atsuyoshi Seki Tadayoshi Kogure Takamasa Ishino Keita Ogawa Kisako Fujiwara Terunao Iwanaga Naoto Fujita Takafumi Sakuma Ryuta Kojima Hiroaki Kanzaki Keisuke Koroki Masanori Inoue Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Tomoko Saito Takayuki Kondo Ryo Nakagawa Shingo Nakamoto Ryosuke Muroyama Tetsuhiro Chiba Ei Itobayashi Masanori Atsukawa Yoshihiro Koma Ryosaku Azemoto Kenji Ito Hideaki Mizumoto Jun Kato Naoya Kato

BMC gastroenterology 23(1) 101-101 2023年3月 [査読有り]

BACKGROUND: Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is to cla...

Impact of skeletal muscle volume on patients with BCLC stage-B hepatocellular carcinoma undergoing sorafenib therapy.

Issei Saeki Takahiro Yamasaki Yurika Yamauchi Tomokazu Kawaoka Shinsuke Uchikawa Akira Hiramatsu Hiroshi Aikata Kazufumi Kobayashi Takayuki Kondo Sadahisa Ogasawara Tetsuhiro Chiba Reo Kawano Kazuaki Chayama Naoya Kato Taro Takami

Cancer medicine 12(9) 10625-10635 2023年3月 [査読有り]

AIM: Skeletal muscle volume has been reported to be an important factor that determines overall survival (OS) and post-progression survival (PPS) in patients with hepatocellular carcinoma (HCC). However, the impact of skeletal muscle volume on HCC...

Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.

Naoya Kanogawa Sadahisa Ogasawara Susumu Maruta Yotaro Iino Masamichi Obu Takamasa Ishino Keita Ogawa Sae Yumita Terunao Iwanaga Hidemi Unozawa Miyuki Nakagawa Kisako Fujiwara Takafumi Sakuma Naoto Fujita Ryuta Kojima Hiroaki Kanzaki Keisuke Koroki Kazufumi Kobayashi Masanori Inoue Soichiro Kiyono Masato Nakamura Takayuki Kondo Tomoko Saito Ryo Nakagawa Shingo Nakamoto Ryosuke Muroyama Tetsuhiro Chiba Ei Itobayashi Yoshihiro Koma Ryosaku Azemoto Jun Kato Naoya Kato

BMC gastroenterology 23(1) 70-70 2023年3月

PURPOSE: Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in patie...

ナルメフェン投与の単一内科での投与成績と今後の課題

清野宗一郎小暮禎祥藤本健太郎弓田冴石野貴雅小川慶太藤原希彩子中川美由貴岩永光巨興梠慧輔神崎洋彰小林和史井上将法中村昌人叶川直哉近藤孝行小笠原定久中本晋吾千葉哲博加藤直也

日本消化器病学会雑誌 120(臨増総会) A400-A400 2023年3月